Vision
Cure – not only treatment of symptoms. Tolerogenics S.à.r.l. aims to become an international leading company in the development of the most effective therapy options for allergy and autoimmune diseases. We believe in our creative scientists and sophisticated management to help patients worldwide living a better life.
Mission
Changing the game. Tolerogenics S.à.r.l. has developed several key technologies to overcome today’s bottlenecks in immunotherapy treatment. Tolerogenic’s has used these technologies to create a novel patent-protected approach of tolerance induction to achieve long-term cure of allergy diseases. The experienced management of Tolerogenics will provide the strategic and regulatory support to bring the products to market.
History
Tolerogenics S.à.r.l. is a private-public-partnership venture with the Luxembourg Institute of Health (LIH), a center of scientific excellence in the field of immunology. The company was founded in July 2016.
Field of business & strategy
Our R&D focuses on new generation immunotherapies for allergic diseases covering unmet needs. For the induction of tolerance, Tolerogenics S.à.r.l. has developed and patent protected key technologies, which can also be used in combination with established allergen- or autoantigen-specific immunotherapy. The intellectual property provides Freedom-To-Operate and will be used to develop therapeutic products for selected diseases. The technology can also be licensed to partner pharma companies.
Team
Tolerogenics S.à.r.l. is managed by an experienced blend of scientists & pharma-professionals covering product and clinical development, business and regulatory expertise.
More information coming soon…